B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CAR15

MOLECULAR TARGET

carbonic anhydrase 15

UniProt: Q99N23NCBI Gene: 8073319 compounds

CAR15 (carbonic anhydrase 15) is targeted by 19 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CAR15

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Celecoxib1.393
2Sulfanilamide1.393
3Zonisamide1.393
4benzolamide1.102
5Mafenide1.102
6Catechin0.691
7Tyrosine0.691
8Acetaminophen Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as0.691
9Resveratrol0.691
10Spermidine0.691
11Tyrosine0.691
12Acetaminophen Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as0.691
13Bicarbonates Inorganic salts that contain0.691
14Bortezomib0.691
15Cyanides Inorganic salts of HYDROGEN CYANIDE containing0.691
16Lacosamide0.691
17Levodopa0.691
18Salicylic Acid0.691
19Sulpiride0.691

About CAR15 as a Drug Target

CAR15 (carbonic anhydrase 15) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 19 compounds with documented CAR15 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CAR15 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.